Proteins

YD23

Cat. No.: HY-153361 CAS No.: 2951015-29-3 Molecular Formula: $C_{38}H_{39}FN_8O_7$

Molecular Weight: 738.76 **PROTACs** Target: Pathway: **PROTAC**

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (135.36 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.3536 mL	6.7681 mL	13.5362 mL
	5 mM	0.2707 mL	1.3536 mL	2.7072 mL
	10 mM	0.1354 mL	0.6768 mL	1.3536 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description YD23 is a SMARCA2 PROTAC. YD23 induces degradation of SMARCA2, which is synthetic lethal to SMARCA4. Moreover, YD23

decreases chromatin accessibility at enhancers of a number of genes including cell cycle and cell growth regulatory genes.

YD23 reduces chromatin accessibility only in SMARCA4 deficient cells mechanistically^{[1][2]}.

 $\mathsf{SMARCA2}^{[1][2]}$ IC₅₀ & Target

REFERENCES

[1]. Kotagiri S, et al. Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer[J]. Cancer Research, 2023, 83(7_Supplement): 1138-

[2]. Kotagiri S, et al. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant tumors[J]. Cancer Research, 2023, 83(7_Supplement): 6289-6289.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com